Management Team at Codexis

As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion. Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.

Mr. Norrett brings over two decades of experience across commercial strategy, business operations and corporate development for both established and emerging biotechnology companies. Most recently, he served as Chief Business Officer of Sierra Oncology.  There, he led commercial operations and corporate development and communications and completed the $1.9 billion acquisition by GSK.  Prior to Sierra Oncology, Mr. Norrett was Chief Commercial Officer at Angion Biomedica, setting commercial strategy and positioning for its pipeline and its successful IPO.  Previously, he served as Vice President of Marketing, Market Access and Commercial Operations at Aimmune Therapeutics, acquired by Nestle Health Science, where he built commercial operations for the launch of Palforzia®, the first approved therapy for pediatric peanut allergy. Prior to joining Aimmune, Mr. Norrett was Vice President, Market Access and Commercial Development at ZS Pharma, acquired by AstraZeneca for $2.7 billion. Mr. Norrett also held increasingly senior commercial leadership roles at Exelixis and Genentech, where he launched multiple products across oncology and rare disease.  Kevin also served as an Associate in SG Cowen’s Health Care Investment Banking Group, closing over 20 transactions worth over $2 billion. Mr. Norrett earned an MBA from the Haas School of Business at the University of California, Berkeley, an MS in Biochemistry and Molecular Biology from University of California, Los Angeles and a BS in Biological Sciences from the University of California, Davis.

Georgia Erbez is a seasoned financial and operations executive, most recently serving as Chief Operating Officer at Walking Fish Therapeutics, a private B cell therapy company. Prior to that, she served as the Chief Financial Officer of Harpoon Therapeutics, a public T cell therapy company. Ms. Erbez also held the role of Chief Business Officer and Chief Financial Officer at Zosano Pharma Corp., and has served as Chief Financial Officer for Revolution Medicines, Asterias Biotherapeutics and Raptor Pharmaceuticals. Earlier in her career, Ms. Erbez held senior positions in investment banking, most recently at Cowen and Company and Jefferies. In addition, she was a Managing Director at Axiom Financial Partners, a life-sciences consulting firm. She currently serves as a member of the board of directors of Coherus BioSciences. Ms. Erbez holds a bachelor’s degree in international relations with an emphasis on economics from the University of California, Davis.

Alison Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. She is former Chief Technical Officer of Allogene Therapeutics, a pioneering clinical-stage company advancing CAR-T therapies. Prior to Allogene she spent a total of 20 years at Amgen, most recently as Senior Vice President, Process Development, and including roles in Supply Chain and Manufacturing. Dr. Moore also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs. Dr. Moore holds a bachelor’s degree in Pharmacology with Honors and a PhD in Cell Biology from Manchester University, England.

Stefan Lutz joined Codexis in 2020 as the Senior Vice President of Research to lead the company’s research team advancing the discovery of proteins. Prior to his arrival in Redwood City, he was a Professor and Chair of the Chemistry Department at Emory University, having joined the university in 2002 and ascending to Chemistry Department Chair in 2014. In addition to his academic work, he has consulted for AgriMetis and served on the scientific advisory boards of ZuvaChem, CODA Genomics Inc. and SynBioX Inc. Stefan has co-authored more than 65 articles published in peer-reviewed journals and six technical books and journals. He holds six patents and is a frequent lecturer and speaker. Dr. Lutz received a BSc in chemistry/chemical engineering from the Zurich University of Applied Sciences, an MSc in Biotechnology from the University of Teesside and a PhD in chemistry from the University of Florida. He was a postdoctoral fellow at Pennsylvania State University.

Ms. Frechou-Armijo is an accomplished human resources leader with over two decades of human resources experience, holding increasingly senior positions within life sciences and technology companies. Most recently, she served as Vice President, Human Resources at Cepheid, a molecular diagnostics company and part of the Danaher family of operating companies.  During her tenure, she led Cepheid’s workforce through rapid expansion and transformation, increasing employee headcount by greater than seven times over a five year period. Prior to Cepheid, Ms. Frechou-Armijo held senior Human Resource roles at Broadcom, where she led workforce strategy, change management and talent management. She also previously held human resources management roles with Molecular Devices, KPMG, and Genencor. She is known for leading through a culture of innovation, collaboration and continuous improvement. Ms. Frechou-Armijo received her BA from California State University, Chico.